Skip to main content
DEI
NYSE Real Estate & Construction

Douglas Emmett Reports Q1 Net Loss, Lower FFO, and Issues Negative 2026 Guidance

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
7
Price
$11.33
Mkt Cap
$1.898B
52W Low
$9.04
52W High
$16.985
Market data snapshot near publication time

summarizeSummary

Douglas Emmett Inc. reported a net loss and decreased FFO for Q1 2026, alongside full-year guidance projecting continued losses, reflecting ongoing challenges in the office market despite strong leasing activity and strategic diversification efforts.


check_boxKey Events

  • Q1 Financial Results Show Decline

    Douglas Emmett reported a net loss of $(2) million for Q1 2026, a significant drop from a $40 million net income in Q1 2025. Funds From Operations (FFO) per fully diluted share also decreased to $0.37 from $0.40 year-over-year.

  • Negative Full-Year 2026 Guidance

    The company issued guidance projecting a full-year 2026 net loss per common share between $(0.20) and $(0.14), and FFO per fully diluted share between $1.39 and $1.45, indicating continued financial headwinds.

  • Strategic Medical Office Acquisition

    A new joint venture, managed by Douglas Emmett, acquired a 5-building, 246,000-square-foot medical office portfolio for $260 million, with the company holding a 13% equity stake in the $150 million equity portion.

  • Mixed Office Leasing Performance

    The company achieved 100,000 square feet of positive absorption and executed 461,000 square feet of new leases, marking its best quarter ever for new leasing volume. However, beginning cash rent on new leases was 7.7% lower than the prior lease's ending cash rent.


auto_awesomeAnalysis

Douglas Emmett's Q1 2026 results reflect a challenging real estate environment, particularly in the office sector, with a notable shift to a net loss and a decline in FFO per share. The full-year guidance for continued net losses and a flat to slightly lower FFO outlook underscores ongoing pressures, including higher interest expenses. While the company demonstrated strong leasing volume in its office portfolio, the 7.7% decrease in beginning cash rent on new leases compared to prior terms indicates persistent pricing challenges. Strategically, the acquisition of a medical office portfolio through a joint venture represents a positive step towards diversification into a more resilient asset class. Additionally, the robust performance of the multifamily segment and the significant residential development pipeline offer potential long-term growth avenues. Investors should monitor the company's ability to execute on its development projects and manage the ongoing headwinds in the office market, particularly the impact of declining cash rents on future profitability.

At the time of this filing, DEI was trading at $11.33 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $9.04 to $16.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed DEI - Latest Insights

DEI
May 08, 2026, 4:29 PM EDT
Filing Type: 10-Q
Importance Score:
7
DEI
May 05, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
7
DEI
May 05, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
DEI
Apr 17, 2026, 4:14 PM EDT
Filing Type: DEF 14A
Importance Score:
8
DEI
Apr 14, 2026, 7:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
DEI
Feb 20, 2026, 4:50 PM EST
Filing Type: 10-K
Importance Score:
7
DEI
Feb 10, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8